Key result
Angiotensin-converting enzyme inhibitors significantly reduced total deaths (OR 0.85; 95% CI 0.78-0.93) and cardiovascular deaths, whereas angiotensin II receptor blockers did not.
Why the study?
Do angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin II receptor blockers in patients with essential hypertension?
Population
73,761 patients with essential hypertension from 17 prospective studies
Comparison
Angiotensin-converting enzyme inhibitors or… vs Control groups within the included prospective…
Design
Meta-analysis
Authors
Loading...
ACE inhibitors may be preferred over ARBs for mortality reduction in essential hypertension; challenges guideline assumptions of class equivalence.
Meta-Analysis (n=73,761)
Do angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin II receptor blockers in patients with essential hypertension?
Effect estimate: OR 0.85 (95% CI 0.78-0.93)
In patients with essential hypertension, ACE inhibitors are more effective than ARBs in reducing total and cardiovascular mortality, although both similarly prevent MI, stroke, and heart failure hospitalizations.
Salvador et al. (2017) conducted a meta-analysis in Essential hypertension (n=73,761). Angiotensin-converting enzyme inhibitors vs. Angiotensin II receptor blockers was evaluated on Total deaths (OR 0.85, 95% CI 0.78-0.93). Angiotensin-converting enzyme inhibitors significantly reduced total deaths (OR 0.85; 95% CI 0.78-0.93) and cardiovascular deaths, whereas angiotensin II receptor blockers did not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: